Related Experiment Videos
Dapsone agranulocytosis in a leprosy patient
1Department of Internal Medicine, J L N Hospital & Research Centre, (MP), India.
Leprosy Review
|September 1, 1994
Summary
Dapsone can cause agranulocytosis, a rare but serious side effect. This case highlights the risk of agranulocytosis in patients treated with dapsone for leprosy, even at low doses.
Area of Science:
- Hematology
- Pharmacology
- Dermatology
Background:
- Dapsone is a key medication for treating leprosy.
- Agranulocytosis is a known rare adverse effect of dapsone.
- This reaction is documented in malaria prophylaxis and dermatological conditions.
Observation:
- A young patient was treated with dapsone (100 mg daily) for borderline-tuberculoid leprosy.
- The patient developed agranulocytosis during treatment.
- The case occurred in a rural healthcare setting.
Findings:
- Dapsone-induced agranulocytosis is infrequently reported in leprosy patients.
- This case underscores the potential for dapsone to cause agranulocytosis in leprosy treatment.
- Even low-dose dapsone (100 mg) can precipitate this severe adverse reaction.
Implications:
- Clinicians should maintain a high index of suspicion for agranulocytosis in patients on dapsone for leprosy.
- Awareness of this rare adverse effect is crucial for timely diagnosis and management.
- Monitoring blood counts may be warranted in specific patient populations or during prolonged dapsone therapy.